Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome combined with VPD/KPD for multiple myeloma with plasmacytoma
ChiCTR2400087424Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, bortezomib, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Overall response rate. Started Jul 2024; status: recruiting.
02
Drugs
mitoxantrone-liposomebortezomibcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400087424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087424.